[Corrigendum] HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance

Zong,Beige; Sun,Lu; Peng,Yang; Wang,Yihua; Yu,Yu; Lei,Jinwei; Zhang,Yingzi; Guo,Shipeng; Li,Kang; Liu,Shengchun

doi:10.3892/or.2021.8146

September-2021 Volume 46 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2021 Volume 46 Issue 3

Full Size Image

Correction Open Access

[Corrigendum] HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance

Authors:
- Beige Zong
- Lu Sun
- Yang Peng
- Yihua Wang
- Yu Yu
- Jinwei Lei
- Yingzi Zhang
- Shipeng Guo
- Kang Li
- Shengchun Liu
View Affiliations / Copyright

Affiliations: Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, P.R. China, Department of Pathology, Chongqing Medical University, Chongqing 400015, P.R. China, Chongqing City Key Lab of Translational Medical Research in Cognitive Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400016, P.R. China

Copyright: © Zong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 195
|
Published online on: July 19, 2021

https://doi.org/10.3892/or.2021.8146
Expand metrics +

Article

Oncol Rep 46: Article no. [Related article:] 138, 2021; DOI: 10.3892/or.2021.8089

Following the publication of this article, the authors realized that the published version of Fig. 4A contained an erroneous label; essentially, the information purported to relate to experiments having been performed with docetaxel should not have been included in this figure.

Figure 4.

HORMAD1 promotes Doc resistance by not enhancing autophagy. (A and B) Western blot analysis of autophagy markers in MDA-MB-436 and MDA-MB-468 cells. P62 and LC3A were decreased and Beclin 1 was increased in the HORMAD1-knockdown group. (C and D) P62 expression was significantly increased in response to HORMAD1 overexpression in MDA-MB-231 cells. (E) Doc-induced apoptosis for 24 h in MDA-MB-231 cells overexpressing HORMAD1 was higher than that in the control group. (F and G) The addition of 3MA significantly inhibited the expression of Beclin 1, while the addition of Doc significantly increased the expression of Beclin 1. (H) Apoptotic rates induced by Doc for 24 h in MDA-MB-436 cells treated with 3MA were higher than those in the control group. (I) The viability of MDA-MB-436 cells treated with 3MA was lower than that of cells in the control group following exposure to Doc for 24 h. (J) Cell viability of MDA-MB-436 treated with si-HORMAD1 was not altered by treatment with Doc for 24 h, with or without 3MA. GAPDH was used as an internal reference protein. *P<0.05, **P<0.01 and ****P<0.001. HORMAD1, HORMA domain-containing protein 1; Doc, docetaxel; 3MA, 3-methyl-adenine; si-NC, small interfering RNA-negative control; si-HORMAD1, siRNA-HORMAD1; ns, no significance; oe, overexpression.

The correctly labelled version of Fig. 4 is shown with the remainder of Fig. 4 on the next page. This change does not affect the data shown in the paper, and the text in the published article did accurately describe the information shown in this figure. The authors sincerely apologize for the error that was introduced during the preparation of this figure, and thank the Editor for allowing them the opportunity to publish a Corrigendum. Furthermore, they regret any inconvenience caused.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

[Corrigendum] HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance

This article is mentioned in:

Article

Figure 4.

Related Articles